E8TN Stock Overview
Engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Eurobio Scientific Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.92 |
| 52 Week High | €17.56 |
| 52 Week Low | €12.50 |
| Beta | -0.35 |
| 11 Month Change | -4.26% |
| 3 Month Change | -11.00% |
| 1 Year Change | -1.69% |
| 33 Year Change | -21.84% |
| 5 Year Change | n/a |
| Change since IPO | 32.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| E8TN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.8% | 0.6% | 0.09% |
| 1Y | -1.7% | -18.6% | 3.1% |
Return vs Industry: E8TN exceeded the German Biotechs industry which returned -16.6% over the past year.
Return vs Market: E8TN underperformed the German Market which returned 3% over the past year.
Price Volatility
| E8TN volatility | |
|---|---|
| E8TN Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: E8TN has not had significant price volatility in the past 3 months.
Volatility Over Time: E8TN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 300 | Denis Fortier | www.eurobio-scientific.com |
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology.
Eurobio Scientific Société anonyme Fundamentals Summary
| E8TN fundamental statistics | |
|---|---|
| Market cap | €139.61m |
| Earnings (TTM) | €4.84m |
| Revenue (TTM) | €130.65m |
28.9x
P/E Ratio1.1x
P/S RatioIs E8TN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E8TN income statement (TTM) | |
|---|---|
| Revenue | €130.65m |
| Cost of Revenue | €79.06m |
| Gross Profit | €51.58m |
| Other Expenses | €46.75m |
| Earnings | €4.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 39.48% |
| Net Profit Margin | 3.70% |
| Debt/Equity Ratio | 54.0% |
How did E8TN perform over the long term?
See historical performance and comparison